Erlotero 150mg tablet

Erlotero 150mg tablet is a chemical based anti cancer medication. Like any other chemotherapeutic drug, it also has multiple side effects that range from common to extreme. Consult your doctor, if symptoms persists for longer period of time or if you experience any of the serious side effects.
● Vomiting
● Nausea
● Fatigue
● Diarrhea
● Decreased Appetite
● Abdominal Pain
● Dry Skin
● Mouth Sores
● Constipation
● Rashes
● Weight Loss
● Headache
● Arthralgia
● Dyspnea
● Pneumonitis
● Vision Related Issues

The standard recommended starting dosage of Erlotero 150mg tablet is once daily. This medicine is taken orally as whole on an empty stomach, without breaking, biting or chewing. Consult your doctor for exact dosage that is especially meant for you.

Erlotero 150mg tablet contains Erlotinib that belongs to the class of tyrosine kinase inhibitor. Erlitinib blocks the abnormal EGFR protein kinase that is responsible for cancer cell growth and proliferation via angiogenesis. Abnormal EGFR protein blockage inhibits cancer cell growth.

• Becker, A., van Wijk, A., Smit, E. F., & Postmus, P. E. (2010). Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 5(9), 1477-1480.
• Tang, P. A., Tsao, M. S., & Moore, M. J. (2006). A review of erlotinib and its clinical use. Expert opinion on pharmacotherapy, 7(2), 177-193.
• Abdelgalil, A. A., Al-Kahtani, H. M., & Al-Jenoobi, F. I. (2020). Erlotinib. In Profiles of drug substances, excipients and related methodology (Vol. 45, pp. 93-117). Academic Press.
• Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., & Ciardiello, F. (2007). Erlotinib in non-small cell lung cancer treatment: current status and future development. The oncologist, 12(7), 840-849.